The Exchange has sought clarification from Aurobindo Pharma on March 05, 2018 with reference to news flashed on www.moneycontrol.com dated March 05, 2018 quoting ‘US FDA observations - Aurobindo Unit 4 inspected by US FDA from February 12-20 and issues 9 observations.’
The above information is a part of company’s filings submitted to BSE.